[Antithrombotic drugs in atrial fibrillation].
Stroke and peripheral thrombo-embolism are common in all forms of atrial fibrillation which is responsible for a hypercoagulable state. Clinical and echocardiographic risk stratification allow therapeutic recommendations among the different antithrombotic strategies used in randomized studies (adjusted-dose oral anticoagulant, aspirin or a combination of aspirin and low-dose oral anticoagulant) in agreement with recent guidelines from the European and American associations of cardiology for the managMent of patients with atrial fibrillation.
Hidden-Lucet
Françoise
F
Unité de rythmologie Institut de cardiologie Groupe hospitalier la Pitié-la Salpêtrière AP-HP 75651 Paris. francoise.hidden-lucet@psl.ap-hop-paris.fr
D000284:Administration, Oral; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D012307:Risk Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D001241:Aspirin